Valuation Tibet Rhodiola Pharmaceutical Holding Co.

Stocks

End-of-day quote Shanghai S.E. 28/10/2026			5-day change	1st Jan Change
35.99 ^CNY	+0.03%		-1.13%	-15.42%

08/10	Tranche Update on Tibet Rhodiola Pharmaceutical Holding Co.'s Equity Buyback Plan announced on December 18, 2025.	CI
13/08	Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Half Year Ended June 30, 2026	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2020	2021	2022	2023	2024	2025
Market Cap ¹	16,681	12,982	8,906	12,099	11,906	13,715
Change	-	-22.18%	-31.4%	35.86%	-1.59%	15.19%
Enterprise Value (EV) ¹	15,908	12,218	7,462	10,226	9,555	11,106
Change	-	-23.19%	-38.93%	37.05%	-6.56%	16.23%
P/E	39.8x	62.3x	24.1x	15.1x	11.3x	14.6x
PBR	6.48x	4.94x	2.96x	3.62x	3.04x	3.61x
PEG	-	-1.2x	0.3x	0x	0.4x	-1.4x
Capitalization / Revenue	12.1x	6.07x	3.49x	3.86x	4.24x	4.6x
EV / Revenue	11.6x	5.71x	2.92x	3.26x	3.4x	3.72x
EV / EBITDA	32.8x	18.7x	9.85x	9.25x	9.87x	11.1x
EV / EBIT	39.1x	21.3x	10.8x	9.85x	10.7x	12x
EV / FCF	207x	-208x	16.3x	17.5x	19.8x	15.9x
FCF Yield	0.48%	-0.48%	6.14%	5.73%	5.06%	6.28%
Dividend per Share ²	0.3923	0.26	0.5738	1.492	1.957	1.757
Rate of return	0.76%	0.65%	2.08%	3.97%	5.3%	4.13%
EPS ²	1.3	0.6462	1.146	2.485	3.26	2.91
Distribution rate	30.2%	40.2%	50.1%	60%	60%	60.4%
Net sales ¹	1,373	2,139	2,555	3,134	2,807	2,982
EBITDA ¹	485	654.2	757.5	1,105	967.6	1,002
EBIT ¹	407.3	572.7	688.3	1,039	893.4	924.7
Net income ¹	418.1	208.9	369.8	800.9	1,051	937.9
Net Debt ¹	-773.1	-763.6	-1,444	-1,873	-2,351	-2,609
Reference price ²	51.75	40.28	27.63	37.54	36.94	42.55
Nbr of stocks (in thousands)	3,22,319	3,22,319	3,22,319	3,22,319	3,22,319	3,22,319
Announcement Date	11/03/21	11/03/22	10/03/23	26/03/24	14/03/25	12/03/26

¹CNY in Million²CNY

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
TIBET RHODIOLA PHARMACEUTICAL HOLDING CO.	-	-	-	-	171.74Cr
ELI LILLY AND COMPANY	37.66x	13.18x	27.98x	0.53%	1,14300Cr
JOHNSON & JOHNSON	39.33x	6.61x	18.6x	1.99%	65TCr
ABBVIE INC.	37.45x	8.4x	17.37x	2.4%	51TCr
ROCHE HOLDING AG	21.46x	5.22x	12.98x	2.51%	38TCr
MERCK & CO., INC.	103.38x	5.8x	24.86x	2.4%	35TCr
NOVARTIS AG	21.99x	5.69x	13.69x	2.94%	29TCr
ASTRAZENECA PLC	22.31x	4.51x	12.87x	1.96%	26TCr
AMGEN INC.	28.42x	7.28x	13.03x	2.25%	24TCr
GILEAD SCIENCES, INC.	-45.78x	7.1x	27.53x	2.07%	20TCr
Average	29.58x	7.09x	18.77x	2.12%	40.29TCr
Weighted average by Cap.	35.27x	8.35x	20.48x	1.8%